中国生化药物杂志
中國生化藥物雜誌
중국생화약물잡지
Chinese Journal of Biochemical Pharmaceutics
2015年
9期
149-151,154
,共4页
罗忠民%路太英%路彦娟%桑璐倩
囉忠民%路太英%路彥娟%桑璐倩
라충민%로태영%로언연%상로천
卡培他滨%晚期胃癌%肿瘤坏死因子-α%白介素-6%血管内皮生长因子%肿瘤标志物
卡培他濱%晚期胃癌%腫瘤壞死因子-α%白介素-6%血管內皮生長因子%腫瘤標誌物
잡배타빈%만기위암%종류배사인자-α%백개소-6%혈관내피생장인자%종류표지물
capecitabine%advanced gastric cancer%tumor necrosis factor α%interleukin-6%vascular endothelial growth factor%tumor biomarkers
目的：观察卡培他滨治疗晚期胃癌（ advanced gastric cancer，AGC）患者的疗效、不良反应及其对患者血清肿瘤坏死因子-α（tumor necrosis factor α，TNF-α）、白介素-6（interleukin-6，IL-6）、血管内皮生长因子（vascular endothelial growth factor，VEGF）和肿瘤标志物CEA、CA19-9、CA125的影响。方法选取郑州大学第一附属医院肿瘤科2012年10月～2014年10月收治的161例晚期胃癌患者，随机将其分为对照组78例与观察组83例。对照组给予常规多西紫杉醇加顺铂方案治疗，观察组在常规治疗基础上给予卡培他滨口服治疗，观察并比较2组患者疗效、不良反应及其对患者血清TNF-α、IL-6、VEGF和肿瘤标志物CEA、CA19-9、CA125水平的影响。结果观察组患者治疗有效率与对照组比较差异无统计学意义（50.6％vs.43.6％，χ2＝0.793，P＝0.373），观察组患者疾病控制率与对照组比较差异无统计学意义（78.3％vs.69.2％，χ2＝1.720，P＝0.190）。观察组患者半年、1年及2年生存率均显著高于对照组（90.4％vs.71.8％，78.3％vs.57.7％，60.2％vs.41.0％，P＜0.05）。观察组患者Ⅰ-Ⅱ度胃肠道不良反应发生率明显高于对照组患者（P＜0.05）。观察组治疗后血清VEGF水平显著低于对照组，而TNF-α、IL-6水平明显高于对照组（P＜0.05）。观察组治疗后CEA、CA19-9、CA125均显著低于对照组（P＜0.05）。结论卡培他滨能够改善机体免疫功能，抑制肿瘤血管形成，治疗晚期胃癌疗效确切，可有效提高患者生存率，且不良反应轻微。这可能与卡培他滨能够调节患者VEGF、TNF-α、IL-6和肿瘤标志物CEA、CA19-9、CA125水平有关。
目的：觀察卡培他濱治療晚期胃癌（ advanced gastric cancer，AGC）患者的療效、不良反應及其對患者血清腫瘤壞死因子-α（tumor necrosis factor α，TNF-α）、白介素-6（interleukin-6，IL-6）、血管內皮生長因子（vascular endothelial growth factor，VEGF）和腫瘤標誌物CEA、CA19-9、CA125的影響。方法選取鄭州大學第一附屬醫院腫瘤科2012年10月～2014年10月收治的161例晚期胃癌患者，隨機將其分為對照組78例與觀察組83例。對照組給予常規多西紫杉醇加順鉑方案治療，觀察組在常規治療基礎上給予卡培他濱口服治療，觀察併比較2組患者療效、不良反應及其對患者血清TNF-α、IL-6、VEGF和腫瘤標誌物CEA、CA19-9、CA125水平的影響。結果觀察組患者治療有效率與對照組比較差異無統計學意義（50.6％vs.43.6％，χ2＝0.793，P＝0.373），觀察組患者疾病控製率與對照組比較差異無統計學意義（78.3％vs.69.2％，χ2＝1.720，P＝0.190）。觀察組患者半年、1年及2年生存率均顯著高于對照組（90.4％vs.71.8％，78.3％vs.57.7％，60.2％vs.41.0％，P＜0.05）。觀察組患者Ⅰ-Ⅱ度胃腸道不良反應髮生率明顯高于對照組患者（P＜0.05）。觀察組治療後血清VEGF水平顯著低于對照組，而TNF-α、IL-6水平明顯高于對照組（P＜0.05）。觀察組治療後CEA、CA19-9、CA125均顯著低于對照組（P＜0.05）。結論卡培他濱能夠改善機體免疫功能，抑製腫瘤血管形成，治療晚期胃癌療效確切，可有效提高患者生存率，且不良反應輕微。這可能與卡培他濱能夠調節患者VEGF、TNF-α、IL-6和腫瘤標誌物CEA、CA19-9、CA125水平有關。
목적：관찰잡배타빈치료만기위암（ advanced gastric cancer，AGC）환자적료효、불량반응급기대환자혈청종류배사인자-α（tumor necrosis factor α，TNF-α）、백개소-6（interleukin-6，IL-6）、혈관내피생장인자（vascular endothelial growth factor，VEGF）화종류표지물CEA、CA19-9、CA125적영향。방법선취정주대학제일부속의원종류과2012년10월～2014년10월수치적161례만기위암환자，수궤장기분위대조조78례여관찰조83례。대조조급여상규다서자삼순가순박방안치료，관찰조재상규치료기출상급여잡배타빈구복치료，관찰병비교2조환자료효、불량반응급기대환자혈청TNF-α、IL-6、VEGF화종류표지물CEA、CA19-9、CA125수평적영향。결과관찰조환자치료유효솔여대조조비교차이무통계학의의（50.6％vs.43.6％，χ2＝0.793，P＝0.373），관찰조환자질병공제솔여대조조비교차이무통계학의의（78.3％vs.69.2％，χ2＝1.720，P＝0.190）。관찰조환자반년、1년급2년생존솔균현저고우대조조（90.4％vs.71.8％，78.3％vs.57.7％，60.2％vs.41.0％，P＜0.05）。관찰조환자Ⅰ-Ⅱ도위장도불량반응발생솔명현고우대조조환자（P＜0.05）。관찰조치료후혈청VEGF수평현저저우대조조，이TNF-α、IL-6수평명현고우대조조（P＜0.05）。관찰조치료후CEA、CA19-9、CA125균현저저우대조조（P＜0.05）。결론잡배타빈능구개선궤체면역공능，억제종류혈관형성，치료만기위암료효학절，가유효제고환자생존솔，차불량반응경미。저가능여잡배타빈능구조절환자VEGF、TNF-α、IL-6화종류표지물CEA、CA19-9、CA125수평유관。
Objective To investigate the effect of capecitabine on serum tumor necrosis factor α( TNF-α) , interleukin-6 ( IL-6 ) , vascular endothelial growth factor (VEGF) and tumor biomarker (CEA,CA19-9 and CA125)levels in patients with advanced gastric cancer (AGC) and its efficacy and adverse reactions.Methods One hundred and sixty-one AGC patients from October 2012 to October 2014 in the hospital were randomly divided into control group (n=78) and observation group (n=83).The control group were treated with cisplatin in combination with docetaxel, while the observation group were treated with capecitabine on the basis of control group.The efficacy, adverse reactions and serum levels of TNF-α, IL-6, VEGF and tumor biomarkers were compared between two groups.Results There was no significant difference in effective rate between observation group and control group (50.6%vs.43.6%,χ2 =0.793,P=0.373) and disease control rate (78.3%vs.69.2%,χ2 =1.720,P=0.190).The half a year,1-year and 2-year survival rates in observation group were significantly higher than those in control group (90.4%vs.71.8%,78.3% vs.57.7%,60.2%vs.41.0%,all P<0.05).The gradeⅠ-Ⅱ adverse reactions of gastrointestinal tract in observation group was significantly higher than control group(P<0.05).After treatment, serum VEGF level in observation group was lower and serum TNF-α,IL-6 levels were higher than those in control group (P<0.05).The serum levels of CEA, CA19-9 and CA125 in observation group were lower than those in control group ( P <0.05 ) .Conclusion Capecitabine could improve immunologic function and inhibit tumor angiogenesis, which has an exact effect and increase survival rate of advanced gastric cancer patients with minor adverse reactions.Its mechanism may be regulating serum VEGF, TNF-α, IL-6 and tumor biomarkers of CEA, CA19-9 and CA125.
